B+
Bull case
25%
Probability
Target price
$73.50
Analysis reference price unavailable
Analysis 2026-02-27 · RankAlpha Sentiment AI
SYRE
Spyre TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$54.29
Analysis reference price unavailable
Analysis 2026-02-27 · RankAlpha Sentiment AI
B-
Bear case
15%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-02-27 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-02-27
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+21.0
Score
AI commentary
Market commentary and price targets skew positive versus the anchor, reflecting analyst optimism around upcoming readouts and commercial potential [#SERP-1]. Short-term sentiment is mixed: some outlets show elevated price targets while others highlight downside scenarios tied to binary trial risk [#SERP-2][#SERP-3]. Overall tone is cautiously constructive but event-driven.
RankAlpha Sentiment AI - 2026-02-27
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-28catalystNear-term quarterly earnings & corporate updateHigh impact
Q1/2026 results and corporate update may include clinical datapoints and guidance that drive a rapid re-rate; market consensus and commentary referenced in analyst summaries [#SERP-3].
2026-09-30eventLate-stage pivotal readout (assumed window end)High impact
Potential pivotal readout for lead asset in H2 2026; no exact public date disclosed so conservatively using window end assumption — outcome would be binary and materially move valuation [#SERP-2].
2027-02-27catalystCommercial uptake and broader pipeline de-riskingHigh impact
Over a full year, successful regulatory steps and early commercial traction could re-rate the company toward peers; long-horizon adoption and multiple program readouts drive this scenario [#SERP-1].
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-27 • Updated nightlySource: Internal modelMethodology